Bronchodilating activity of oral clenbuterol in asthmatic children after single administration of different dosages

Boner, Attilio; Bennati, D; Castellani, C.; Sette, L.; Schiassi, M

doi:10.1002/ppul.1950030110

Cited by 6 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…None of the studies available to date have determined the specific duration of pharmacological actions relative to plasma concentration of CLB (Shapland et al. , 1981; Boner et al. , 1987a, b).…”

Section: Discussionmentioning

confidence: 99%

Pharmacokinetics and disposition of clenbuterol in the horse

Soma

Uboh

Guan

et al. 2004

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

The pharmacokinetics of clenbuterol (CLB) following a single intravenous (i.v.) and oral (p.o.) administration twice daily for 7 days were investigated in thoroughbred horses. The plasma concentrations of CLB following i.v. administration declined mono-exponentially with a median elimination half-life (t(1/2k)) of 9.2 h, area under the time-concentration curve (AUC) of 12.4 ng.h/mL, and a zero-time concentration of 1.04 ng/mL. Volume of distribution (V(d)) was 1616.0 mL/kg and plasma clearance (Cl) was 120.0 mL/h/kg. The terminal portion of the plasma curve following multiple p.o. administrations also declined mono-exponentially with a median elimination half-life (t(1/2k)) of 12.9 h, a Cl of 94.0 mL/h/kg and V(d) of 1574.7 mL/kg. Following the last p.o. administration the baseline plasma concentration was 537.5 +/- 268.4 and increased to 1302.6 +/- 925.0 pg/mL at 0.25 h, and declined to 18.9 +/- 7.4 pg/mL at 96 h. CLB was still quantifiable in urine at 288 h following the last administration (210.0 +/- 110 pg/mL). The difference between plasma and urinary concentrations of CLB was 100-fold irrespective of the route of administration. This 100-fold urine/plasma difference should be considered when the presence of CLB in urine is reported by equine forensic laboratories.

show abstract

Section: Discussionmentioning

confidence: 99%

Pharmacokinetics and disposition of clenbuterol in the horse

Soma

Uboh

Guan

et al. 2004

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

show abstract

“…That dosage was calculated based on the metabolic body weight that 10 μ g/kg/day in rats is equivalent to 1 μ g/kg/day in humans, a dose safely used in asthma treatments [25, 35]. The dose in the current study was 120 μ g/day (~2 μ g/kg/day for a 60 kg person).…”

Section: Discussionmentioning

confidence: 99%

Randomized, Double-Blind, and Placebo-Controlled Trial of Clenbuterol in Denervated Muscle Atrophy

Jiang

Zhang

et al. 2011

ISRN Pharmaceutics

View full text Add to dashboard Cite

Objectives. β 2-adrenergic agonists, such as clenbuterol, have been shown to promote the hypertrophy of healthy skeletal muscles and to ameliorate muscle wasting in a few pathological conditions in both animals and humans. We intended to investigate the clinical efficacy of clenbuterol on attenuating denervation-induced muscle atrophy. Methods. A double-blind, placebo-controlled, parallel, and randomized trial was employed. 71 patients, suffering from brachial plexus injuries, were given either clenbuterol (60 μg, bid) or placebo for 3 months. Before and at the end of the study, patients were given physical examinations, biopsies of biceps brachii, electromyograms (EMGs), and other laboratory tests. Results. Compared with placebo treatment, clenbuterol significantly mitigated the decreases in cross-sectional areas of type I and II muscle fibers and alleviated the reduction in fibrillation potential amplitudes, without any adverse effects. Conclusions. Clenbuterol safely ameliorated denervated muscle atrophy in this cohort; thus larger clinical studies are encouraged for this or other β 2 agonists on denervation-induced muscle atrophy.

show abstract

Comparison of the protective effect and duration of action of orally administered clenbuterol and salbutamol on exercise‐induced asthma in children

Vallone

Brighenti³

et al. 1988

Pediatric Pulmonology

View full text Add to dashboard Cite

Clenbuterol (C), a long-acting beta 2-selective bronchodilator was compared with salbutamol (S) in exercise-induced asthma (EIA) at two premedication time levels. Sixteen asthmatic children with EIA living at an altitude of 1,750 m were treated with C (0.001 mg/kg) and S (0.12 mg/kg), administered randomly in a double-blind cross-over study 90 and 300 minutes before exercise tests of running on a treadmill for 6 minutes. Pulmonary functions were evaluated prior to the administration of the drugs and immediately before, at the end of, and 2, 5, 10, 15, 20, and 25 minutes after exercise tests. In the preliminary screening exercise test the mean fall of FEV1 was 41.1%, but it was 21.0% and 27.1% after S and 21.9% and 19.9% after C administered 90 and 300 min prior to the test, respectively. Salbutamol administered 300 minutes before the test was statistically less effective than the same drug administered 90 minutes before the test or C administered 300 minutes before the test. Therefore, we can conclude that clenbuterol provides a more lasting protection than salbutamol in EIA.

show abstract

Bronchodilating activity of oral clenbuterol in asthmatic children after single administration of different dosages

Cited by 6 publications

References 6 publications

Pharmacokinetics and disposition of clenbuterol in the horse

Pharmacokinetics and disposition of clenbuterol in the horse

Randomized, Double-Blind, and Placebo-Controlled Trial of Clenbuterol in Denervated Muscle Atrophy

Comparison of the protective effect and duration of action of orally administered clenbuterol and salbutamol on exercise‐induced asthma in children

Contact Info

Product

Resources

About